Chattopadhyay Anandini, Goyal Falak, Sehrawat Abhishek, Sidhu Inderpal Singh, Monga Vikramdeep, Bhatti Gurjit Kaur, Bhatti Jasvinder Singh
Laboratory of Translational Medicine and Nanotherapeutics, Department of Human Genetics and Molecular Medicine, School of Health Sciences, Central University of Punjab, 151401, Bathinda, India.
Department of Zoology, Sri Guru Gobind Singh College, Sector 26, 160019, Chandigarh, India.
Curr Treat Options Oncol. 2025 Aug 19. doi: 10.1007/s11864-025-01343-3.
The ongoing challenge of addressing breast cancer, one of the most prevalent cancers and a principal cause of mortality among women globally, has reached a critical juncture with the advent of precision medicine and the promise of nanotechnology. As the scientific community's understanding of breast cancer's genomic landscape has deepened, it has become evident that a one-size-fits-all approach to treatment is obsolete. The evolution from rudimentary immunohistochemical classifications to intricate molecular profiling has ushered in an era where therapy is increasingly tailored to the individual's genetic makeup, environmental factors, and lifestyle choices. This shift towards personalized, biomarker-driven treatments not only aims to enhance prognosis but also to minimize adverse effects by meticulously matching therapy to the unique molecular characteristics of each tumor. The integration of nanotechnology, particularly through the deployment of nanoparticles for targeted drug delivery and nano-theranostics, represents a groundbreaking stride in oncological treatment. This convergence of precision medicine and nanotechnology in breast cancer care suggests a future where combination therapies and multifunctional approaches could potentially outsmart drug resistance and augment treatment efficacy. However, the path forward is fraught with challenges such as overcoming inherent tumor heterogeneity and improving the accessibility of cutting-edge treatments. The exploration of these innovative strategies in breast cancer therapeutics underscores the critical need for a multifaceted approach to cancer care, emphasizing the potential of these advances to revolutionize treatment paradigms and offer new hope to patients.
乳腺癌是全球女性中最常见的癌症之一，也是主要的死亡原因，随着精准医学的出现和纳米技术的前景，应对乳腺癌这一持续存在的挑战已到了关键时刻。随着科学界对乳腺癌基因组格局的理解不断深入，显而易见，一刀切的治疗方法已过时。从基本的免疫组织化学分类到复杂的分子谱分析的演变，迎来了一个治疗越来越根据个体基因构成、环境因素和生活方式选择量身定制的时代。这种向个性化、生物标志物驱动治疗的转变不仅旨在改善预后，还通过精心使治疗与每个肿瘤的独特分子特征相匹配来尽量减少不良反应。纳米技术的整合，特别是通过部署纳米颗粒进行靶向药物递送和纳米诊疗，代表了肿瘤治疗方面的一项开创性进展。精准医学与纳米技术在乳腺癌治疗中的融合预示着一个未来，即联合疗法和多功能方法可能会战胜耐药性并提高治疗效果。然而，前进的道路充满挑战，如克服固有的肿瘤异质性和提高前沿治疗的可及性。在乳腺癌治疗中探索这些创新策略凸显了对癌症护理采取多方面方法的迫切需求，强调了这些进展有可能彻底改变治疗模式并为患者带来新希望。
